SML1945
IMB-808
≥98% (HPLC)
别名:
2,3-Dihydro-N-methyl-N-[2-oxo-2-[(2,3,4-trifluorophenyl)amino]ethyl]-1,4-benzodioxin-6-carboxamide, N-Methyl-N-(2-oxo-2-((2,3,4-trifluorophenyl)amino)ethyl)-3,4-dihydro-2H-benzo[b][1,4] dioxin-7-carboxamide
产品名称
IMB-808, ≥98% (HPLC)
InChI
1S/C18H15F3N2O4/c1-23(9-15(24)22-12-4-3-11(19)16(20)17(12)21)18(25)10-2-5-13-14(8-10)27-7-6-26-13/h2-5,8H,6-7,9H2,1H3,(H,22,24)
InChI key
XITZPIXICJOKTF-UHFFFAOYSA-N
SMILES string
FC1=C(NC(CN(C)C(C2=CC(OCCO3)=C3C=C2)=O)=O)C=CC(F)=C1F
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 2 mg/mL, clear
storage temp.
2-8°C
Biochem/physiol Actions
IMB-808 is a potent Liver X receptor α and β (LXRα/β) partial dual agonist that promotes expression of genes related to reverse cholesterol transport (including ABCA1 and ABCG1), and associated with cholesterol metabolism pathway in multiple cell lines (including ApoE). Also IMB-808 promotes cholesterol efflux from macrophages and reduced the accumulated lipids of foam cells.
potent Liver X receptor α and β (LXRα/β) partial dual agonist
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
新产品
此项目有
Ni Li et al.
Molecular pharmacology, 91(4), 264-276 (2017-01-15)
Activation of liver X receptor (LXR) is associated with cholesterol metabolism and anti-inflammatory processes, which makes it beneficial to antiatherosclerosis therapy. Nevertheless, existing agonists that target LXR, for example TO901317, are related to unwanted side effects. In the present study
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持